Biaxin, Biaxin XL Articles
Profit drop for Taisho, but firm sees recovery
5 June 2009
Japan stock market week to May 25, 2009
27 May 2009
Diapharm organizes GMP inspection at Ranbaxy
13 May 2009
Japan stock market week to March 23, 2009
30 March 2009
Takeda files Japanese NDA for H. Pylori combo
30 March 2009
Japan stock market week to Nov 24, 2008
24 November 2008
ALS files cethromycin NDA for use in CAP
6 October 2008
UK study finds excessive antibiotic Rx
15 September 2008
Japan stock market week to June 2, 2008
9 June 2008
Taisho's sales jump 4.7% in fiscal 2007
2 June 2008
Japan stock market week to April 7, 2008
14 April 2008
Abbott Labs returns to profit in 4th-qtr 2007
28 January 2008
Japan stock market week to Nov 19, 2007
26 November 2007
Cethromycin "non-inferior" to Biaxin in CAP
2 July 2007
Oscient completes Ph IV enrollment in Factive trial early
5 February 2007
Japan stock market week to July 10, 2006
17 July 2006
Teva updates on generic Biaxin
3 July 2006
Australia certification for Ind Swift Labs
22 May 2006
Japan recalculates eight drug ingredients due to high sales
27 February 2006
Japan's Taisho sees first nine month sales, earning slip but still ahead of forecast
6 February 2006
Taisho OTC drug sales fall 8%, Rx rises 3%
5 December 2005
Stock Commentary - New York
25 July 2005
Japan stock market week to June 20
27 June 2005
Stock Commentary - New York
6 June 2005
Taisho's fiscal year sees 2.4% sales drop
30 May 2005
Teva gets FDA OK for generic clarithromycin
23 May 2005
Andrx reports 33% income rise
16 May 2005
Stock Commentary - New York
11 April 2005
Japan stock market week to March 21
28 March 2005
Tokyo pharma stocks - week to August 9
16 August 2004
Stock Commentary - New York
5 July 2004
Stock Commentary - New York
19 April 2004
Bayer's Avelox superior in AECB
15 March 2004
Tokyo pharma stocks - week to August 11
18 August 2003
Taisho and Toyama form joint sales firm
3 February 2003
Abbott's profits up 2%, forecasts lowered
27 January 2003
Axcan files for approval of Helicide in USA and Canada
5 October 2001
FDA extends Biaxin label to include CAP
8 August 2001
Analysts expectant on future prospects for Canada's Axcan Pharma
13 February 2001
Chinese pharma sales, other industry data
6 February 2001
Aventis reveals first Phase III Ketek data at ICAAC, sees $1 billion in
28 September 2000
Aventis reveals first Phase III Ketek data at ICAAC
20 September 2000
Stock Commentary Tokyo
31 August 2000
Slight slip in Tokyo pharma stocks
22 August 2000
Abbott Labs net income rises 6.2%
13 July 2000
Abbott launches once-daily Biaxin in USA
27 April 2000
Once-daily Biaxin approved in USA
8 March 2000
First approval for B-MS' Tequin heats up antibiotic sector - update
30 December 1999
Takeda licenses novel diabetes drug
11 October 1999
P&U to file NDA for linezolid by year-end, new Phase III data
29 September 1999
Kangyu acquires Zhejiang firm
27 September 1999
-Abbott and Wyeth Laboratories launch HeliClear
18 February 1999
Orchid Building New Drug Plant in India
9 November 1998
US Majors Post Strong Earnings For 3rd Quarter
15 October 1998
Evolution In Migraine Therapy; New Triptans, And Beyond
10 September 1998
Canada Approves Ulcer Combination Therapy
27 August 1998
Abbott Labs Impacted By Strength Of Dollar
14 July 1998
Warnings To Be Added To US Propulsid Labeling
1 July 1998
USA's Most-Dispensed Rx Drugs In April 1998
20 May 1998
Expanded Warnings For J&J's Hismanal
11 February 1998
Biaxin As Effective As Co-Amoxiclav In Bronchitis
11 February 1998
Grepafloxacin Cleared For Marketing In USA
11 November 1997
Drug Promo Meetings "Up 61% Since 1995"
27 October 1997
Greek Govt Adjusts Prices Of 6,009 Drugs
3 October 1997
ROXIS - More Support For Antibiotics In Heart Disease
13 August 1997
Prevacid OK'd For H pylori eradication
26 June 1997
Pylorid Vs Omeprazole For HP Eradication
19 May 1997
US 4th Qtr/Year-End Results See Strong Growth
27 January 1997
Astra's Losec "World's No One Drug In 1998-2000"
16 December 1996
Good Japanese Interim Results, Despite Price Cuts
25 November 1996
Triple Therapy For H Pylori
28 October 1996
P&G To Launch Low-Cost Helicobacter Regimen In USA
2 September 1996
Glaxo Wellcome's Tritec Cleared In USA
19 August 1996
ChemTrak Gets US Appro for H pylori kit
8 July 1996
1st H pylori Treatment Approved In USA
22 April 1996
Losec "Will Be The World's Top-Selling Drug In 2000"
26 February 1996
FDA Year-End Approvals Round-Up
8 January 1996
Ulcer Therapy Market Set For Transformation
18 December 1995
Mixed Interims From Japanese Drug Majors
20 November 1995
Glaxo Wellcome Unveils Revamped Pipeline
20 November 1995
Abbott Labs' 3rd Qtr Net Earnings Up 8.7%
16 October 1995
"Only H pylori And NSAIDs Cause Ulcers"
25 September 1995
Glaxo Wellcome's Pylorid Launched In First Market
18 September 1995
First Approval For GW's Ranitidine Bismuth Citrate
24 July 1995
Merck pipline report
3 July 1995
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
